Ropivacine and Chloroprocaine mixture — Competitive Intelligence Brief

Ropivacine and Chloroprocaine mixture (Ropivacine and Chloroprocaine mixture) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Local anesthetic combination. Area: Anesthesia / Pain Management.

marketed Local anesthetic combination Voltage-gated sodium channels Anesthesia / Pain Management Small molecule

Target snapshot

Ropivacine and Chloroprocaine mixture (Ropivacine and Chloroprocaine mixture) — University of New Mexico. This mixture of two local anesthetics blocks sodium channels in nerve fibers to prevent pain signal transmission.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Ropivacine and Chloroprocaine mixture TARGET	Ropivacine and Chloroprocaine mixture	University of New Mexico	marketed	Local anesthetic combination	Voltage-gated sodium channels
tetracaine HCl and oxymetazoline HCL	tetracaine HCl and oxymetazoline HCL	Louisiana State University Health Sciences Center in New Orleans	marketed	Local anesthetic with vasoconstrictor combination	Voltage-gated sodium channels (tetracaine); alpha-2 adrenergic receptors (oxymetazoline)
Venlafaxine and Lamotrigine	Venlafaxine and Lamotrigine	University Health Network, Toronto	marketed	SNRI + anticonvulsant combination	Serotonin transporter, norepinephrine transporter, voltage-gated sodium channels, glutamate modulation
Multiple injection local anesthetic	Multiple injection local anesthetic	Hôpital du Valais	marketed	Local anesthetic	Voltage-gated sodium channels
Depofoam bupivacaine	Depofoam bupivacaine	The Cleveland Clinic	marketed	Local anesthetic (liposomal formulation)	Voltage-gated sodium channels
intravenous saline plus perineural bupivacaine	intravenous saline plus perineural bupivacaine	Sherif Mohamed Abd el moneim Soaida, MD	marketed	Local anesthetic with supportive fluid therapy	Voltage-gated sodium channels (Nav)
Triamcinolone acetonide-Ketorolac-Ropivacaine	Triamcinolone acetonide-Ketorolac-Ropivacaine	United Health Services Hospitals, Inc.	marketed	Combination injection (corticosteroid + NSAID + local anesthetic)	Glucocorticoid receptor (triamcinolone); COX-1/COX-2 (ketorolac); voltage-gated sodium channels (ropivacaine)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Local anesthetic combination class)

1. University of Belgrade · 2 drugs in this class
2. Cedars-Sinai Medical Center · 1 drug in this class
3. Cutia Therapeutics（Wuxi）Co.,Ltd · 1 drug in this class
4. East Carolina University · 1 drug in this class
5. Galderma R&D · 1 drug in this class
6. Hadassah Medical Organization · 1 drug in this class
7. University of Alabama at Birmingham · 1 drug in this class
8. University of New Mexico · 1 drug in this class
9. Ain Shams University · 1 drug in this class
10. University of Wisconsin, Madison · 1 drug in this class